91 related articles for article (PubMed ID: 9596291)
1. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Kimerling ME; Phillips P; Patterson P; Hall M; Robinson CA; Dunlap NE
Chest; 1998 May; 113(5):1178-83. PubMed ID: 9596291
[TBL] [Abstract][Full Text] [Related]
2. Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".
Aarnoutse R; Ruesen C; Burhan E; van Crevel R; Ruslami R
Antimicrob Agents Chemother; 2014; 58(1):629-30. PubMed ID: 24363391
[No Abstract] [Full Text] [Related]
3. Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.
Court R; Chirehwa MT; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; McIlleron H
Int J Tuberc Lung Dis; 2019 Oct; 23(10):1068-1074. PubMed ID: 31627771
[No Abstract] [Full Text] [Related]
4. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.
McIlleron H; Hundt H; Smythe W; Bekker A; Winckler J; van der Laan L; Smith P; Zar HJ; Hesseling AC; Maartens G; Wiesner L; van Rie A
Int J Tuberc Lung Dis; 2016 Jul; 20(7):915-9. PubMed ID: 27287644
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.
Guerra RL; Conde MB; Efron A; Loredo C; Bastos G; Chaisson RE; Golub JE
Respir Med; 2010 May; 104(5):754-7. PubMed ID: 20202806
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with adverse drug reactions or death in very elderly hospitalized patients with pulmonary tuberculosis.
Yagi M; Shindo Y; Mutoh Y; Sano M; Sakakibara T; Kobayashi H; Matsuura A; Emoto R; Matsui S; Nakagawa T; Ogawa K
Sci Rep; 2023 Apr; 13(1):6826. PubMed ID: 37100850
[TBL] [Abstract][Full Text] [Related]
7. Are all antibiotic persisters created equal?
Shultis MW; Mulholland CV; Berney M
Front Cell Infect Microbiol; 2022; 12():933458. PubMed ID: 36061872
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
Anderson G; Vinnard C
J Clin Pharmacol; 2022 Oct; 62(10):1206-1214. PubMed ID: 35588142
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Alcohol Use Disorder on Tuberculosis: A Review of the Epidemiology and Potential Immunologic Mechanisms.
Wigger GW; Bouton TC; Jacobson KR; Auld SC; Yeligar SM; Staitieh BS
Front Immunol; 2022; 13():864817. PubMed ID: 35432348
[TBL] [Abstract][Full Text] [Related]
10. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.
Nardotto GHB; Bollela VR; Rocha A; Della Pasqua O; Lanchote VL
Clin Transl Sci; 2022 Feb; 15(2):514-523. PubMed ID: 34670022
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Intravenous Isoniazid and Ethambutol Administration in Patients with Tuberculosis Meningoencephalitis and HIV Infection.
Butov D; Feshchenko Y; Kuzhko M; Gumenuik M; Yurko K; Grygorova A; Tkachenko A; Nekrasova N; Tlustova T; Kikinchuk V; Peshenko A; Butova T
Tuberc Respir Dis (Seoul); 2020 Jan; 83(1):96-103. PubMed ID: 31905437
[TBL] [Abstract][Full Text] [Related]
12. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
Mtabho CM; Semvua HH; van den Boogaard J; Irongo CF; Boeree MJ; Colbers A; Burger DM; van Crevel R; van der Ven AJAM; Kibiki GS; Tostmann A; Aarnoutse RE
J Antimicrob Chemother; 2019 Dec; 74(12):3537-3545. PubMed ID: 31651031
[TBL] [Abstract][Full Text] [Related]
13. Determinants of serum concentration of first-line anti-tuberculosis drugs from China.
Lei Q; Wang H; Zhao Y; Dang L; Zhu C; Lv X; Wang H; Zhou J
Medicine (Baltimore); 2019 Oct; 98(41):e17523. PubMed ID: 31593125
[TBL] [Abstract][Full Text] [Related]
14. Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes.
Ramachandran G; Chandrasekaran P; Gaikwad S; Agibothu Kupparam HK; Thiruvengadam K; Gupte N; Paradkar M; Dhanasekaran K; Sivaramakrishnan GN; Kagal A; Thomas B; Pradhan N; Kadam D; Hanna LE; Balasubramanian U; Kulkarni V; Murali L; Golub J; Gupte A; Shivakumar SVBY; Swaminathan S; Dooley KE; Gupta A; Mave V;
Clin Infect Dis; 2020 Mar; 70(7):1463-1470. PubMed ID: 31075166
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
16. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.
Myers B; Bouton TC; Ragan EJ; White LF; McIlleron H; Theron D; Parry CDH; Horsburgh CR; Warren RM; Jacobson KR
BMC Infect Dis; 2018 Sep; 18(1):488. PubMed ID: 30268101
[TBL] [Abstract][Full Text] [Related]
17. Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update.
Pettit AC; Shepherd BE; Sterling TR
Curr Opin HIV AIDS; 2018 Nov; 13(6):469-477. PubMed ID: 30222609
[TBL] [Abstract][Full Text] [Related]
18. Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
Kumar AKH; Chandrasekaran V; Kannan T; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2018 Mar; 147(3):287-292. PubMed ID: 29923518
[TBL] [Abstract][Full Text] [Related]
19. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.
Ramachandran G; Agibothu Kupparam HK; Vedhachalam C; Thiruvengadam K; Rajagandhi V; Dusthackeer A; Karunaianantham R; Jayapal L; Swaminathan S
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242663
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
